Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789252 | 0.89 | CHRM2 (0.53) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL20995891 | 0.89 | CHRM2 (0.53) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7926056 | 0.84 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7920287 | 0.84 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7926060 | 0.84 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL8969129 | 0.83 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| SCHEMBL16672047 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL11503102 | 0.78 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL11784008 | 0.78 | LMNA (0.31) | — | |
| SCHEMBL7678513 | 0.77 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868041-B2 | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20090270493-A1 | CYCLIC 1-(ACYLOXY)-ALKYL PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7569576-B2 | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060122125-A1 | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2006-06-08 | — | — | US | disclosed |
| US-7026351-B2 | Gamma-aminobutyric acid (GABA); prodrugs of gabapentin and/or pregabalin; for sustained release; for treatment of pain and epilepsy | XENOPORT, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20030236200-A1 | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270493-A1 | CYCLIC 1-(ACYLOXY)-ALKYL PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB3, GABRB2 | CHRM2 2263/4885CHRM1 1791/4885CHRM4 1639/4885 |
| US-20060122125-A1 | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB3, GABRB2 | CHRM2 2263/4885CHRM1 1791/4885CHRM4 1639/4885 |
| US-20030236200-A1 | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB3, GABRB2 | CHRM2 2263/4885CHRM1 1791/4885CHRM4 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.